Loading…

Discovery of an Orally Active Series of Isoxazoline Glycoprotein IIb/IIIa Antagonists

Using isoxazoline XR299 (1a) as a starting point for the design of highly potent, long-duration GPIIb/IIIa antagonists, the effect of placing lipophilic substituents at positions α and β to the carboxylate moiety was evaluated. Of the compounds studied, it was found that the n-butyl carbamate 24u ,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 1997-06, Vol.40 (13), p.2064-2084
Main Authors: Xue, Chu-Biao, Wityak, John, Sielecki, Thais M, Pinto, Donald J, Batt, Douglas G, Cain, Gary A, Sworin, Michael, Rockwell, Arlene L, Roderick, John J, Wang, Shuaige, Orwat, Michael J, Frietze, William E, Bostrom, Lori L, Liu, Jie, Higley, C. Anne, Rankin, F. Wayne, Tobin, A. Ewa, Emmett, George, Lalka, George K, Sze, Jean Y, Di Meo, Susan V, Mousa, Shaker A, Thoolen, Martin J, Racanelli, Adrienne L, Hausner, Elizabeth A, Reilly, Thomas M, DeGrado, William F, Wexler, Ruth R, Olson, Richard E
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Using isoxazoline XR299 (1a) as a starting point for the design of highly potent, long-duration GPIIb/IIIa antagonists, the effect of placing lipophilic substituents at positions α and β to the carboxylate moiety was evaluated. Of the compounds studied, it was found that the n-butyl carbamate 24u , exhibited superior potency and duration of ex vivo antiplatelet effects in dogs. Replacement of the benzamidin-4-yl moiety with alternative basic groups, elimination of the isoxazoline stereocenter, and reversal of the orientation of the isoxazoline ring resulted in lowered potency and/or duration of action.
ISSN:0022-2623
1520-4804
DOI:10.1021/jm960799i